The increasing use of opioids in pregnant women has led to an alarming rise in the number
of cases of neonates with drug-induced withdrawal symptoms known as neonatal opioid …

Introduction Rates of neonatal opioid withdrawal syndrome (NOWS) have paralleled the rise
of opioid use during pregnancy. While short-term phenotypic symptoms of NOWS are well …

Purpose To explore whether MR fingerprinting (MRF) scans provide motion‐robust and
quantitative brain tissue measurements for non‐sedated infants with prenatal opioid …

BackgroundEvidence on neonatal withdrawal syndrome following antidepressant
intrauterine exposure is limited, particularly for antidepressants other than selective …

Objectives To compare clinical outcomes for infants with neonatal opioid withdrawal
syndrome (NOWS) treated with buprenorphine or morphine. Study design Retrospective …

The rising prevalence of early-life opioid exposure has become a pressing public health
issue in the US Neonates exposed to opioids in utero are at risk of experiencing a …

The opioid epidemic in the United States has led to an increasing number of pregnant
patients with opioid use disorder (OUD) presenting to obstetric units. Caring for this complex …

Background Maternal opioid use (MOU) remains a public health concern. Studies have
demonstrated significant increases in MOU, but estimates using ICD-10-CM or stratified by …

Administration of a widely used 5‐hydroxytryptamine receptor (5HT3AR) antagonist
(ondansetron) potently inhibited the development of experimentally induced opioid …

This month, Clinical Therapeutics tackles alcohol use disorders, along with their treatments
and integrated, comprehensive therapies. Authors in this Special Topic Update highlight that …